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Summary An attempt has been made to reverse cachexia and to selectively deprive the tumour of metabolic
substrates for energy production by feeding a ketogenic regime, since ketone bodies are considered important
in maintaining homeostasis during starvation. As a model we have used a transplantable mouse
adenocarcinoma of the colon (MAC 16) which produces extensive weight loss without a reduction in food
intake. When mice bearing the MAC16 tumour were fed on diets in which up to 80% of the energy was
supplied as medium chain triglycerides (MCT) with or without arginine 3-hydroxybutyrate host weight loss
was reduced in proportion to the fat content of the diet, and there was also a reduction in the percentage
contribution of the tumour to the final body weight. The increase in carcass weight in tumour-bearing mice
fed high levels of MCT was attributable to an increase in both the fat and the non-fat carcass mass. Blood
levels of free fatty acids (FFA) were significantly reduced by MCT addition. The levels of both acetoacetate
and 3-hydroxybutyrate were elevated in mice fed the high fat diets, and tumour-bearing mice fed the normal
diet did not show increased plasma levels of ketone bodies over the non-tumour-bearing group despite the
loss of carcass lipids. Both blood glucose and plasma insulin levels were reduced in mice bearing the MAC16
tumour and this was not significantly altered by feeding the high fat diets. The elevation in ketone bodies may
account for the retention of both the fat and the non-fat carcass mass. This is the first example of an attempt
to reverse cachexia by a diet based on metabolic differences between tumour and host tissues, which aims to
selectively feed the host at the expense of the tumour.
Progressive weight loss is a characteristic feature of advanced Conyers et al., 1979b). The lack of ketosis in cancer patients,
cancer and is an important cause of death as well as despite the loss of body fat, may be related to an elevated
contributing to the refractoriness of chemotherapy (Van Eys, basal metabolic rate (Theologides, 1979) and the high energy
1982). The cachectic syndrome is characterised by a expenditure by the liver in the recirculation of lactate into
depletion of the host muscle and adipose mass and a glucose. The lack of ketosis may explain the increased total
reduction in insulin secretion (Theologides, 1979; Goodlad et body protein turnover in cancer patients (Heber et al., 1982)
al., 1975) accompanied by a lower serum glucose level and and the decreased insulin secretory capacity.
an elevation in serum unesterified fatty acids (Bibby et al., Tumours, especially those with a poor blood supply might
1987). be expected to utilize glucose as the predominant metabolic
In contrast with acute starvation gluconeogenesis from fuel, since the Embden Meyerhof pathway is the only means
both alanine (Waterhouse et al., 1979) and glycerol of ATP production which does not require oxygen. Thus
(Lundholm et al., 1982) is increased in cachectic cancer fatty acids and ketone bodies might be expected to be
patients and this is accompanied by an elevated Cori cycle metabolized poorly. Indeed, in a range of murine and human
activity (Holroyde & Reichard, 1981). The latter appears to tumours very low, or no activity of 3 oxo acid-CoA
be due to an elevated tumour glycolysis leading to an transferase has been observed (Tisdale & Brennan, 1983).
increased lactate production, with a corresponding increase This enzyme is regarded as the key enzyme in ketone body
in the proportion of glucose derived from lactate. metabolism. Thus a low carbohydrate ketogenic diet might
During acute starvation mobilization of free fatty acids be expected to prevent host catabolism during cachexia and
(FFA) from adipose tissue provides a source of energy for in addition reduce the rate of growth of tumours which
organs such as muscle and liver. Excess FFA are converted depend on glucose as an energy source (Tisdale, 1982). We
in the liver to ketone bodies (acetoacetate and 3-hydroxy- have investigated this possibility in an experimental model of
butyrate) which in turn serve as a source of energy for cachexia which utilizes the MAC16 adenocarcinoma of the
extrahepatic tissues including the brain (Owen et al., 1967). colon transplanted in NMR1 mice. This tumour, which is a
This leads to a decrease in overall glucose requirement and a moderately well-differentiated adenocarcinoma, produces
decrease in gluconeogenesis from alanine and lactate in the extensive weight loss in the host without a concurrent
liver. In addition ketone bodies directly reduce protein reduction in food intake (Bibby et al., 1987).
degradation in muscle, possibly due to an inhibitory action
on the oxidation of branched-chain amino acids, thus
reducing the supply of gluconeogenic precursors. High
ketone body levels also stimulate insulin secretion from the Materials and methods
pancreas (Hawkins et al., 1971).
Although extensive mobilization of adipose tissue occurs Chemicals were obtained from Sigma Chemical Co., Poole,
in advanced cancer ketonuria is an uncommon phenomenon Dorset, UK, unless otherwise stated. A Wako NEFA C kit
in both cancer patients (Conyers et al., 1979a) and in for FFA determination in plasma was obtained from Alpha
tumour-bearing rodents (Bibby et al., 1987; Mider, 1951). Laboratories Ltd., Hampshire, UK. 3-Hydroxybutyrate,
However, if either fasted cancer patients or tumour-bearing arginine salt was kindly donated by Solvay and Cie,
mice are provided with an exogenous supply of fatty acids, Brussels, Belgium. Rat and mouse breeding diet, soya,
ketonemia is observed suggesting no impairment of the liver sodium caseinate, rodent 006 premix and dicalcium
in its ability to synthesize ketone bodies (Magee et al., 1979; phosphate were all purchased from Pilsburys Ltd.,
Birmingham, UK. A medium chain triglyceride emulsion was
Correspondence: M.J. Tisdale. obtained from Scientific Hospital Supplies Ltd., Liverpool,
Received 8 December 1986; and in revised form, 11 March 1987. UK.40 M.J. TISDALE et al.
Animals health of the animals. Body weights were measured daily at
Pure strain male NMRI mice (age 6-8 weeks) were used. the same time of day. At the end of the study blood samples
Fof the MAC16 tumour were implanted into the were collected by cardiac puncture under anaesthesia using a frlag
t
. P t c mixture of halothane, oxygen and nitrous oxide (halothane, fank by means Of a trocar. Positive takes can only be 2 5% 0_. lin
identified 14 days after implantation (Bibby et al., 1987). All 2.5/; 02.' 0.5mlmin ; N20, 0.7mlmin 1). Blood was
mice were given free acces toratandmouscollected in haparinized syringes and all blood samples were
and wer for 8ray after tuo tran
an atton. taken between 9.00 and 11.00a.m. Blood glucose and free and water for 8 days after tumour transplantation. fatty acids were determined immediately and the remaining
samples were deproteinised for the determination of Diets acetoacetate, 3-hydroxybutyrate and lactate. The dietary
The standard diet was rat and mouse breeding diet which studies were repeated at least three times with a minimum of
contained 50% carbohydrate and supplied 11.5% of the 5 animals in each group. Results were analysed statistically
energy as fat. Isocaloric, isonitrogeneous diets with an using the analysis of variance or F-ratio.
increasing proportion of energy from fat were prepared by
decreasing the carbohydrate content and supplying the Metabolite assays
remaining energy from a medium chain triglyceride emulsion Blood glucose Whole blood (0.2ml) was used and glucose
(Table I). The ketogenic diets were presented to the animals was determined using the o-toluidine reagent kit (Sigma).
as a paste to minimise food scatter. Food consumption and Acetoacetate and 3-hydroxybutyrate levels were measured by
water intake was monitored daily and food wastage was also the method of Mellanby and Williamson (1974) and
determined. Arginine 3-hydroxybutyrate was supplemented Williamson and Mellanby (1974) respectively. Lactate levels
in the drinking water, at a concentration of 3 mgml - The were determined by the method of Gutmann and Wahlefield
average daily water intake was 4ml per mouse. Diets were (I974). FFA levels were determined by a Wako NEFA C
initiated 8 days after tumour transplantation and continued kit. Insulin levels were determined by radioimmunoassay until day 28. All experiments were terminated at this time using human insulin binding reagent (K303810) (Wellcome
since control animals had lost 25% of the body weight and Laboratories) and a rat insulin standard (NOVO;
further weight loss would have lead to a deterioration in the R8308081). Total carcassfat and water content. Each carcass
was placed in an oven at 80°C until constant weight was
Table I Composition of ketogenic dietsb reached. Carcasses were then reweighed and the total fat
content was determined by the method of Lundholm et al.
NFEa 50.3 25.4 22.8 (1980). Water content for the muscle and total carcass was
calculated from the wet and dry weights.
Percentage ofenergyfromfat 11.5 68.0 80.0
Raw materialsc Results
Soya (dehulled) 349.2 361.21
Limestone - 7.45 9.1
Bentonite - 75.20 66.0 The effect of feeding a diet with increasing proportions of
Salt 5.83 5.8 energy derived from MCT on host body weight and tumour
Dicalcium phosphate 38.97 40.3 size as well as the total amount of calories consumed by the
Methionine 1.28 1.9 various dietary groups is shown in Table II. Mice bearing
Sodium caesinate 26.47 the MAC16 tumour show an average weight loss of 20%
Rat and mouse breeding diet 1,000 34.07 during the period of the study when fed the normal pelleted
Rodent 006 premix 17.76 18.0 diet and this occurs without a drop in calorie consumption
Triglyceride emulsiond - 443.77 497.7 when compared with the corresponding non tumour-bearing
group (Table II). Weight loss produced by the MAC16 aNFE is the nitrogen free extract and is a term used as an tuour reduce in mice fed di cnann te tAn
indication of carbohydrate content; bDiets are isocaloric,
isonitrogenous and with an increasing proportion of the energy from 68% MCT and there is a small, but not significant,
fat; cInclusion rates of raw materials are in gkg-1. Energy enhancement when arginine 3-hydroxybutyrate iS included.
2737kcalkg-t Protein 200gKg-' in all diets; dTriglyceride emulsion When expressed as a percentage body weight loss diets
contained 52% w/w MCT, 48% water and the following percentages containing 80% MCT cause a reduction by 50% of the
of fatty acids: C6, 1.1; C8, 81.1; C1IO 15.7; C129 2.1. cachectic effect of the tumour. This reduction in weight loss
Table II The effect of dietary modification on weight loss and tumour size in male NMR1 mice bearing the MAC16 adenocarcinoma (A)
and in non tumour-bearing mice (B)
Tumour weight
Final weight Final weight (g) Totalfood
Initial weight (g)±s.e.m. Tumour weight Final body weight consumed
Dietary treatment (g)±s.e.m. - tumour weight Initial weight (g) (g)±s.e.m. (g) kcalper mouse
A
Normal diet 31.1 +0.5 25.2+ 1.9 0.81 1.2 +0.04 0.048 202+10
68% MCT 29.0+0.7 22.6+_1.7 0.84 0.96+0.11 0.043 224+30
68% MCT+3-hydroxybutyrate 30.8+0.85 27.1_+1.0 0.88 0.89+0.10 0.030 223+22
80% MCT 30.5+0.5 28.4+1.4 0.93 0.80+0.23a 0.028 228+32
80% MCT+3-hydroxybutyrate 32.1+0.4 29.1+1.7 0.91 0.78+0.lla 0.026 216+_17
B
Normal diet 32.6+0.6 33.5+0.6 1.03 - -201 + 10
68% MCT 31.9+1.1 32.8+1.1 1.03 --214+32
68% MCT+3-hydroxybutyrate 32.9+1.4 33.4+0.5 1.06 - 231 +23
80% MCT 29.5+0.3 31.1+1.2 1.05 --219+30
80% MCT+3-hydroxybutyrate 34.4+_1.8 34.6+1.4 1.01 -214+17
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occurs without a significant change in total calories in carcass fat when compared with non tumour-bearing mice
consumed (Table II). Mice fed diets containing 80% MCT (P<0.01) which is proportional to the size of the tumour
with or without 3-hydroxybutyrate show a significant (Bibby et al., 1987). Body fat depletion in tumour-bearing
reduction in tumour size when compared with those fed the animals is prevented to some extent by increasing the
normal pelleted diet (P<0.01) and all mice fed high levels of contribution of energy derived from triglycerides, and the
MCT show a reduction in the percentage contribution of the percentage contribution to the total carcass weight almost
tumour to the final body weight. Non-tumour bearing mice doubles when animals are fed high levels of MCT. Increasing
fed the high MCT diets show no significant differences in the fat content of the diet also decreases the carcass lipid
food consumption or weight from those fed the normal diet. content of non tumour-bearing mice possibly due to
Mice bearing the MAC16 tumour show a significant insufficient carbohydrate to supply oxaloacetate for citrate
(P<0.05) depression of the non-fat carcass mass when formation.
compared with control non tumour-bearing mice when The total carcass water of both tumour-bearing and non
expressed as an absolute weight (Table III). However, when tumour-bearing mice does not vary with alterations in the
the non-fat carcass weight is expressed as a percentage of the percentage of energy derived from MCT (Table III). Thus
final body weight there is no difference between tumour- the increase in weight of mice fed diets with increasing
bearing and non tumour-bearing mice, despite the fact that proportions of energy supplied by MCT derives mainly from
the former have lost over 20% of their body weight. This an increase in the carcass dry weight.
suggests that the carcass dry weight is reduced in direct There is no significant alteration in the levels of
proportion to the change in total carcass weight (Table III). circulatory FFA in tumour-bearing mice when compared
Increasing the percentage of MCT in the diets of tumour- with non tumour-bearing mice fed the normal diet (Table
bearing mice leads to an increase in the carcass non-fat mass IV). With the exception of non tumour-bearing animals fed
only with 80% MCT+3-hydroxybutyrate and there is no 68% MCT the FFA levels were all lower in both groups of
difference from controls in the percentage contribution to animals when they were fed increasing levels of MCT.
the total carcass weight with any of the diets. However, tumour-bearing animals fed the 80% MCT diets
The total fat content of the carcasses of mice fed have significantly higher levels of plasma FFA than the
increasing proportions of triglycerides in the diet is shown in corresponding non tumour-bearing groups.
Table III. Mice bearing the MAC16 tumour show a decrease Blood levels of acetoacetate and 3-hydroxybutyrate from
Table III Effect of feeding a high fat diet on body composition of NMRI mice bearing the MAC16
adenocarcinoma (A) and in non tumour-bearing mice (B)
Non-fat mass Percent Carcassfat Percent Water
Dietary treatment (g)±s.e.m. carcass weight (g)±s.e.m. carcass weight (%)±s.e.m.
A
Normal diet 7.1 +0.5b 28 0.32+O.Olb 1.3 71+0.8
68% MCT 6.9+0.6fa 30 0.48+0.13fa 2.1 68+0.6
68% MCT+3-hydroxybutyrate 7.4+0.6f 28 0.66+0.13f 2.4 70+0.6
80% MCT 7.3+0.3e 26 0.58+0.07fd 2.0 72+0.1
80% MCT+3-hydroxybutyrate 8.2+0.3fda 28 0.53 +0.06fd 1.8 70+0.4
B
Normal diet 10.8+0.6 26 1.82+0.22 6.4 68+ 1.5
68% MCT 10.0+0.7d 28 0.97+0.2 3.0 71+0.7
68% MCT+3-hydroxybutyrate 9.3+0.13c 28 0.38+0.2f 1.1 71+0.7
80% MCT 8.2+0.4e 26 0.62+0.08f 2.0 72+0.5
80% MCT+3-hydroxybutyrate 10.2+0.7d 30 1.01+0.3 2.9 67+1.2
ap<0.05 from corresponding non tumour bearing group; bp<0.01 from corresponding non tumour-bearing
group; CP<0.05 from tumour-bearing group fed normal diet; dp<0.01 from tumour-bearing group fed
normal diet; ep<0.05 from non tumour-bearing group fed normal diet; fP<0.01 from non tumour-bearing
group fed normal diet.
Table IV Effect of dietary modification on blood levels of FFA, acetoacetate, 3-hydroxybutyrate, lactate and insulin in NMR1 mice bearing
the MAC16 adenocarcinoma (A) and in non tumour-bearing mice (B)
Glucose FFA 3-Hydroxybuturate Acetoacetate Lactate Insulin
Dietary treatment mg 100ml+s.e.m. mM+s.e.m. mm+s.e.m. mM+s.e.m. mM+s.e.m. ngml- I +s.e.m.
A
Normal diet 98+ gb 1.01 +0.16 0.09+0.02 0.05+0.02 7.3+0.9 0.67+0.08a
68% MCT 117+20 0.80+O.15d 0.34+0.06 0.17+0.05afc 3.3+0.9e 1.02+0.4
68% MCT+3-hydroxybutyrate 81 + 7f 0.49+0.09d 0.28+0.03fdb 0.18+0.06bfc 5.6+1.2 0.94+0.16
80% MCT 101+ 9f 0.77+0.07d 0.34+0.07f 0.3l+0.l10 6.5+0.7a 0.70+0.10~
80% MCT+3-hydroxybutyrate 112+12C 0.76+O.OSda 0.28+0.09cd 0.50 +O.lSed 6.2_+0.5 0.54+O.O3
B
Normal diet 138+ 8 0.89_+0.07 0.08_+0.01 0.05_+0.01 6.8+0.8 1.66+0.17
68% MCT 122+_ 7 l.28+O.29e 0.17+_0.07e 0.65+_ .l9fd 5.6+0.2 0.72+0.10
68% MCT+3-hydroxybutyrate 127_+18 0.45+0.13fd 0.38+0.11fd 0.64+007fd 5.9+13e 1.07+0.14c
80% MCT 130+ 3 O.40+O.05 0.18+_ .05~ 0.14+_0.05~ 3.3+_0.9c 1.20O_O.11ld
80% MCT+3-hydroxybutyrate 96+ _lSe 0.49+_O.lOed 0.34+_ .O4fd 0.47+_ .O6fd 6.4+_ 1.2 0.81 +0.08
ap<0.05 from corresponding non tumour-bearing group; bp<0.01 from corresponding non tumour-bearing group; Cp<0.05 from tumour-
bearing group on normal diet; dp<0.01 from tumour-bearing group on normal diet; ep<0.05 from non tumour-bearing group on normal diet;
fp<0.01 from non tumour-bearing group on normal diet.42 M.J. TISDALE et al.
each of the dietary groups is shown in Table IV. The total on mice fed normal diets (Gabor et al., 1985). A gain in
ketone body concentration in tumour-bearing mice fed the body weight of patients with metastatic malignant disease
normal diet is not elevated above that of non tumour- was reported when given a commercial fat emulsion by i.v.
bearing mice, despite the decrease in carcass lipids. Feeding a infusion (Waterhouse & Nye, 1961). In addition there was
high fat diet to both tumour and non tumour-bearing mice evidence of nitrogen and potassium saving and movement
results in a significant elevation of the plasma levels of both towards a positive caloric balance.
acetoacetate and 3-hydroxybutyrate, over those fed the In the present study weight loss was reduced by up to
normal diet, although again there is no significant elevation 50% in NMR1 mice bearing the MAC16 adenocarcinoma of
in the tumour-bearing groups over that of non tumour- the colon when they were fed a dietary regime with
bearing groups for a given level of dietary fat. In fact for the increasing proportions of energy derived from medium chain
68% MCT diet the levels of acetoacetate are significantly triglycerides. Body composition analysis showed retention of
lower in the tumour-bearing groups over that of the non both fat and non-fat carcass mass in animals fed high levels
tumour-bearing groups. Despite the inclusion of large of MCT. No change was evident in the water content of the
amounts of 3-hydroxybutyrate in the diets there is not carcasses between the different dietary groups. Despite the
appreciable ketosis in these animals. This may be due to a high intake of triglycerides plasma levels of acetoacetate and
high metabolic activity in mice, and to the excretion of large 3-hydroxybutyrate were not markedly elevated, presumably
amounts of ketone bodies in the urine of mice fed high fat due to the high metabolic rate of the mice and excretion of
diets (results not shown). Increasing the lipid content of the ketone bodies in the urine. Also the circulatory levels of
diet causes a reduction in the 3-hydroxybutyrate:acetoacetate FFA were not elevated in either tumour-bearing or non
ratio in both groups of mice. There is no effect of a high tumour-bearing mice fed the high fat diets, although there
MCT diet on the level of 3-oxo acid-CoA transferase in the was some evidence for increased peripheral tissue deposition
tumours. The level of this enzyme in the MAC16 tumour has of fat in tumour-bearing, but not in non tumour-bearing
been shown to be much lower than that of normal colonic mice. This suggests increased catabolism of fat by #-
mucosa (Tisdale & Brennan, 1986). Thus the MAC16 oxidation. In view of the decreased oxygen tension in
tumour has a low capacity to metabolize ketone bodies and tumours coupled with a decreased enzymatic capacity to deal
this is not altered by dietary modulation. with ketone bodies (Tisdale & Brennan, 1983) utilization of
The blood glucose level in tumour-bearing mice fed the both FFA and ketone bodies by the tumour might be
normal diet is significantly lower than in non tumour- expected to be, minimal, which may account for the
bearing mice (P<0.01) and the plasma insulin level is also reduction in tumour size observed. Normal tissues would be
significantly reduced (Table IV). Non tumour-bearing mice able to utilize both FFA and ketone bodies as an energy
fed a diet with increasing proportions of energy derived from source and the hyperketonemia would promote nitrogen
MCT do not have a significantly different blood glucose or conservation (Sherwin et al., 1975), which in turn would
plasma insulin level from those fed a normal diet, and, reduce gluconeogenic precursors to the liver. Loss of body
tumour-bearing mice fed the high fat diets do not have a fat in non tumour-bearing mice fed high MCT diets is not
significantly different blood glucose level from the due to a reduced dietary intake, but may be associated with
corresponding non-tumour bearing groups. The presence of the decreased carbohydrate content of the diet.
arginine 3-hydroxybutyrate in the diet does not affect plasma We have previously shown (Bibby et al., 1987) that weight
insulin levels. loss produced by the MCA16 tumour is proportional to
Lactate levels in tumour-bearing mice fed the normal diet tumour size and thus it is possible that the prevention of
do not differ significantly from non tumour-bearing mice weight loss by the high fat regimes may be due to the
(Table IV). The effect of increasing triglyceride levels in the reduction in tumour size. However, a plot of tumour weight
diet is to decrease the blood lactate level, although this is versus weight loss for mice fed the high fat diets shows a
only significant with 68% MCT in the tumour-bearing mice. significant increase in intercept (by F test) from those fed a
There is no alteration in the plasma levels of pyruvate. This normal diet. Thus the high fat regime reduces weight loss to
suggests decreased utilization of glucose with increasing fat a greater extent than might be anticipated from the
consumption. reduction in tumour size. Moreover, the positive intercept on
the tumour weight axis suggests that weight loss is totally
prevented at small tumour masses by increasing the fat
Discussion content of the diet.
The reduction in tumour size produced by diets containing
The metabolism of a number of tumours is quantitatively 3-hydroxybutyrate does not result from a direct antitumour
different from that of normal cells. Most tumours have a effect since in vitro arginine 3-hydroxybutyrate has no effect
high dependence on glycolysis and are relatively deficient in on tumour growth at concentrations up to 6mM.
oxidative capacity, making it theoretically possible to Although nutritional support can improve the nutritional
differentially feed the host and not the tumour. Using a rat status of the host large quantities of exogenous substrates
transplantable mammary carcinoma Buzby et al. (1980) were are associated with an increased metabolic rate and
able to show that when fat was provided as the primary stimulation of tumour growth. By increasing the lipid
source of calories a more favourable host: tumour balance contribution to the nutritional regime we have shown that it
was obtained, when measured by the relative rates of growth is possible to prevent host weight loss while reducing tumour
of each. Isocaloric consumption of a diet high in fat and size. In addition such dietary modification may have a
protein and low in carbohydrate significantly prolonged the synergistic action with conventional radiotherapy and
survival of MCA-sarcoma bearing rats (Demetrakopoulos & chemotherapy, since initial results suggest a reduction in
Rosenthall, 1982) and prevented anorexia in rats implanted necrosis and an increase in vasculature when animals are fed
with Walker 256 carcinosarcoma (Enrione & Black, 1983). high levels of MCT (Tisdale & Brennan, unpublished
Also dietary induced ketosis reduced the number of Bl16 results). Such a diet should be achievable clinically since it
melanoma deposits in the lungs of C57BL/6 mice by two- has been reported (Phinney et at., 1983) that when normal
thirds (Magee et at., 1979) although we have recently human subjects were fed a diet in which 85% of the calories
reported a failure of systemic ketosis to control cachexia and were supplied as fat it was well tolerated and there was no
growth rate of the Walker 256 carcinosarcoma in rats measurable impairment of hepatic, renal, cardiac or
(Fearon et at., 1985). However, the growth of a haemopoietic function.
transplantable mammary adenocarcinoma in BALB/c mice
has been shown to be significantly greater for mice fed diets This work has been supported by a grant from the Cancer Research
containing 10% corn oil than for mice fed 10% Campaign. We thank Mr D. Lambert, Department of Molecular
hydrogenated cottonseed oil, although no data was presented Sciences, Aston University for measurement of plasma insulin levels.CANCER CACHEXIA AND FAT 43
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